BTL's new laser division introduces a dual-wavelength erbium system; market already saturated with erbium and hybrid platforms.
BTL has established a dedicated laser division and introduced EXOLASE ONE, marketed as the world's first fused erbium laser. The system combines erbium wavelengths in a single handpiece, targeting ablative and non-ablative skin resurfacing, scar revision, and pigmentation.
The erbium laser space is crowded. Cynosure, Cutera, Lumenis, and Synergon all offer erbium or hybrid platforms. BTL's entry hinges on differentiation—whether fused wavelengths deliver clinical or economic advantages over sequential or separate-handpiece systems. The company's strength lies in its installed base of RF and ultrasound devices, which could drive cross-selling.
Fused erbium enters a saturated market; differentiation will hinge on clinical outcomes and economics, not novelty.
For practices, the question is whether EXOLASE ONE's specs (power, pulse duration, cooling, footprint) justify replacing or supplementing existing erbium systems. BTL's pricing and lease terms, plus training and support, will matter more than the "first fused" claim. Evaluate against Cynosure's Icon and Cutera's Xeo as baseline comparisons.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
